Mastocytosis
Immunology·MeSH: Immune System Diseases
Prevalence
30.0 / 100K
5 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| ayvakit | Blueprint Medicines Corp (BPMC) |
Phase 1(2)
Preclinical(1)
| Drug | Company |
|---|---|
| ht-kit | Hoth Therapeutics, Inc. (HOTH) |
Phase 4(1)
| Drug | Company |
|---|---|
| avapritinib | Blueprint Medicines Corp (BPMC) |
Compare drugs
Frequently asked questions
How many drugs are in development for Mastocytosis?
BioSniper tracks 5 drugs in development for Mastocytosis across 2 companies.
How many clinical trials target Mastocytosis?
There are 1 clinical trial targeting Mastocytosis tracked by BioSniper.
What is the prevalence of Mastocytosis?
The estimated prevalence of Mastocytosis is approximately 30.0 per 100,000 population.
Deep-dive into Mastocytosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis